Skip to content

Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening

Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening in Hospitals Serving Diverse Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06192511
Acronym
MICI
Enrollment
5980
Registered
2024-01-05
Start date
2024-05-15
Completion date
2028-04-30
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Implementation Science, Informed Consent, Neonatal Screening

Keywords

newborn screening, informed consent, biobanking

Brief summary

The purpose of this study is to implement an electronic consent education process for the retention and research use of residual dried bloodspots at four hospitals in Michigan and assess the impact of the new education, both on patients and hospital staff. The research team will recruit women who have just given birth to answer surveys about the Michigan BioTrust consent process. Surveys will be collected from participants in the hospital and again four weeks later. The research team will collect survey data from patient participants at each hospital prior to hospital staff implementation of the new education process and again after staff implementation.

Detailed description

The research team will compare a prospective observational control group enrolled during pre-implementation data collection within a hospital (n=2,990) to the implemented consent process group enrolled at the same hospital after implementation (2,990). Implementation will consist of hospital staff providing patients with access to a website with detailed written descriptions and a video about the Michigan BioTrust. The current standard of care, that will be maintained in addition to the new website, involves providing the patient with a brochure and descriptive information from hospital staff about the Michigan BioTrust. A research staff member will approach patients and ask if they are willing to answer some surveys about the BioTrust consent process. After agreeing to answer the surveys, the researcher will provide them with a direct link to the research survey. If the participant does not have a phone or tablet with them, the research team member will provide a tablet upon which they can answer the questions on the survey. All participating women or men will complete a survey 1) in the day following the BioTrust Consent and 2) at roughly 4 weeks later by email, text or telephone. Hospital employees involved in the implementation will also answer surveys about potential sustainability immediately after completing training and again after several months of implementation.

Interventions

BEHAVIORALEducational Website and Video

The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.

Sponsors

Erin Rothwell
Lead SponsorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult (\> 18 years) * English, Spanish or Arabic speaking * Just gave birth and currently a patient in the Mother \& Baby Unit in the hospital

Exclusion criteria

* Parents of infants who are born pre-term (\< 37 weeks gestation) * Parents of infants in the Neonatal Intensive Care Unit * Parents of infants being put up for adoption or in situations where legal guardianship is unknown at the time of birth

Design outcomes

Primary

MeasureTime frameDescription
Consent and biobanking knowledge scoresAdministered immediately after the intervention and at 4 week follow-upKnowledge will be measured with with 23 questions specific to the setting of NIPS testing, and including the multidimensional measure of informed choice (MMIC). Scored will range from 0 (no knowledge) to 23 (extremely high knowledge)
Decisional regretAdministered at the 4-week follow-upThe Residual Decisional Regret measure assesses a person's feelings of regret after making a decision. Scores range from 1 to 5 with lower scores indicating better outcomes
Decisional ConflictAdministered immediately after the intervention and at 4 week follow-upThe Decisional Conflict survey will determine participant uncertainty in the decision process. DCS score ranges from 0 (no decisional conflict) to 100 (extremely high decisional conflict)
Consenting ratesObtained from the state 6 months after the end of data collectionFrom the state the research team will obtain whole hospital consenting rates (people who make a decision, whether it's yes or no) for the 6-month time period before and after the Implementation
Biobanking ratesObtained from the state 6 months after the end of data collectionThe research team will summarize the percentage who opt to participate in biobanking before and after implementation using state level data

Countries

United States

Contacts

CONTACTErin Johnson, PhD
erin.p.johnson@hsc.utah.edu801-587-8578
CONTACTValerie Joseph
valerie.joseph@hsc.utah.edu801-587-2249
PRINCIPAL_INVESTIGATORErin Rothwell, MD

University of Utah

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026